OCERA THERAPEUTICS, INC.
OCERA THERAPEUTICS, INC. (OCRX): 1 pipeline candidate · ~8 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.3 months
D/E 3.05 · 0% dilution
Lead: Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for OCERA THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$14.4M
Quarterly Burn
$5.3M
Runway
8.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| ocr-002 | Phase 2 |
Frequently asked questions
How many drug candidates are in OCERA THERAPEUTICS, INC.'s pipeline?
OCERA THERAPEUTICS, INC. (OCRX) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is OCERA THERAPEUTICS, INC.'s lead drug candidate?
OCERA THERAPEUTICS, INC.'s most advanced tracked candidate is ocr-002 (Phase 2) for Hepatic encephalopathy (HE).
What is OCERA THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, OCERA THERAPEUTICS, INC. has approximately 8.3 months of cash runway.
Who is the CEO of OCERA THERAPEUTICS, INC.?
Redwood City is the chief executive officer of OCERA THERAPEUTICS, INC. (OCRX).
Get the full picture on OCERA THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.